BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity

Hairy cell leukemia (HCL) shows unique clinicopathological and biological features. HCL responds well to purine analogs but relapses are frequent and novel therapies are required. BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-cell lymphomas, including HCL-like leukem...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Pettirossi, Valentina, Santi, Alessia, Imperi, Elisa, Russo, Guido, Pucciarini, Alessandra, Bigerna, Barbara, Schiavoni, Gianluca, Fortini, Elisabetta, Spanhol-Rosseto, Ariele, Sportoletti, Paolo, Mannucci, Roberta, Martelli, Maria Paola, Klein-Hitpass, Ludger, Falini, Brunangelo, Tiacci, Enrico
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2015
Assuntos:
Plenary Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4366655/
https://ncbi.nlm.nih.gov/pubmed/25480661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-10-603100
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares